Research Article

Relationship between the Degree of Illness in Elderly Patients with Rheumatoid Arthritis and Parameters of Musculoskeletal Ultrasound and Oswestry Dysfunction Index and Clinical Value Analysis

Danping Shen,1,2 Zun Li,1,2 Zhe Shan,2,3 Jue Wang,1,2 and Yujie Ren1,2

1 Department of Ultrasound, Wujin Hospital Affiliated with Jiangsu University, Changzhou 213000, Jiangsu, China
2 The Wujin Clinical College of Xuzhou Medical University, Changzhou 213000, Jiangsu, China
3 Department of Blood Rheumatism, Wujin Hospital Affiliated with Jiangsu University, Changzhou 213000, Jiangsu, China

Correspondence should be addressed to Yujie Ren; renyujie@wjhospital.org.cn

Received 22 June 2022; Revised 12 July 2022; Accepted 18 July 2022; Published 2 August 2022

Academic Editor: Bo Li

Copyright © 2022 Danping Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The aim of the study is to explore the relationship between the degree of illness in elderly patients with rheumatoid arthritis (RA) and parameters of musculoskeletal ultrasound (MSUS) and Oswestry Dysfunction Index (ODI) and its clinical value.

Methods. The clinical data of 100 elderly patients with RA admitted to our hospital from May 2016 to May 2022 were retrospectively analyzed. The patients were divided into four groups, including the remission group (DAS28 ≤ 2.6, n = 25), low activity group (2.6 ≤ DAS28 ≤ 3.2, n = 25), middle activity group (3.2 ≤ DAS28 ≤ 5.1, n = 25), and high activity group (DAS > 5.1, n = 25) according to the disease activity score-28 (DAS28). All patients underwent ultrasonic detection to compare the relationship between the degree of illness in elderly patients with RA and parameters of MSUS and ODI.

Results. The total semiquantitative score of MSUS and ODI score in the remission group were obviously lower than those in the other three groups (P < 0.001). The degree of illness in elderly patients with RA was positively correlated with parameters of MSUS (r = 0.886, P < 0.001). The degree of illness in elderly patients with RA was positively correlated with ODI (r = 0.907, P < 0.001).

Conclusion. The degree of illness in elderly patients with RA is closely related to parameters of MSUS and ODI, and the parameters of MSUS have a higher evaluation value for the degree of illness in elderly patients with RA, which are correlated with ODI.

1. Introduction

As a common disease in the rheumatic immunology department, rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease, with aggressive and symmetric polyarthritis as the main clinical manifestations [1], and its clinical symptoms are limb fatigue, muscle soreness in the whole body, and joint swelling. At present, the complex etiology and pathogenesis of RA have not been fully elucidated, which may be related to microbial infection, smoking, and autoimmunity, and heterogeneity exists even in the same type, with different etiology in various types [2]. Furthermore, the disease often involves the small joints of extremities like hands and feet, which seriously affects the joint function and daily life in the late stage, and even loses the self-care ability. In addition, the adverse factors such as toxicity and side effects and economic pressure in the treatment process cause great pressure on the patient’s body and mind, resulting in a significant decline in quality of life [3]. According to relevant literature, the incidence of RA is the highest in systemic connective tissue disease mostly in women aged 35–55 years old, with the incidence as 0.49%, and the incidence and disability rate of RA increase with age [4]. According to statistics, the number of patients with RA accounts for about 0.99% of the global population, with the prevalence rate in China at about 0.29%, and the ratio of male to female morbidity is about 1 : 2.4 [5]. Skielta Mattias et al. [6] have noted that the 4–9 years of mutilation rate is
about 59.99% if RA patients do not receive timely treatment, and the disability rate over 25 years is 89.99%, which seriously affects the health of patients.

Wang Qiyu et al. [7] have pointed out that early diagnosis of RA, assessment of disease activity, and analysis of ODI are the key to treatment selection and prognosis improvement. Radiological imaging is a common clinical diagnosis and treatment method, but this method is expensive and has a radioactive injury, which is not easily accepted by patients [8, 9]. However, characterized by no radiation, no wound, and convenient operation, musculoskeletal ultrasound (MSUS) has been widely used in the early diagnosis of RA, but there are also shortcomings in this diagnostic technique, for example, the examination results are easily affected by the operators, and the lesions in the large joint cannot be effectively examined. Zhang Shibin et al. [10] have found that the degree of illness in patients is associated with a semiquantitative score of MSUS. At the same time, the scale of the Oswestry Disability Index (ODI) was designed by Fairbank and other experts in 1976. After a large number of trial questionnaires, version 1.0 of ODI was formed in 1980, which was widely promoted at the Paris International Conference on Studies of Lumbar Vertebra, and the evaluation of the ODI scale adopted in elderly patients with RA can directly reflect the degree of illness [11]. It has been confirmed that the ODI scale, as a measurement instrument for functional impairment, has good reliability and validity in chronic low back pain and lumbar disc herniation [12]. However, there are few reports on the relationship between the degree of illness in elderly patients with RA and parameters of MSUS and ODI and clinical value. Based on this, this study adopted the scheme and carried out the joint clinical intervention on subjects in order to provide more clinical evidence-based proof for such patients.

2. Materials and Methods

2.1. General Information. The clinical data of 100 elderly patients with RA admitted to our hospital from May 2016 to May 2022 were retrospectively analyzed. The patients were divided into four groups, including the remission group (DAS28 ≤ 2.6, n = 25), low activity group (2.6 ≤ DAS28 ≤ 3.2, n = 25), middle activity group (3.2 ≤ DAS28 ≤ 5.1, n = 25), and high activity group (DAS > 5.1, n = 25) according to the disease activity score-28 (DAS28). This study was consistent with the Declaration of Helsinki (2013) [13].

2.2. Recruitment of Study Subjects

2.2.1. Inclusion Criteria. The inclusion criteria were as follows: (1) those who met the diagnostic criteria of RA in the Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis 2018 [14] and were diagnosed with RA by clinic and imaging examinations, with the manifestations of clinical symptoms as muscle soreness in the whole body, articular pain, and appetite depression. (2) Those who had symptoms like varying degrees of joint swelling, pain, and activity limitation. (3) Those who were above the age of 18, without the limitation of gender. (4) Those who did not take the related drugs such as anti-infective drugs or glucocorticoids affecting the study results within three months before joining the group.

2.2.2. Exclusion Criteria. The exclusion criteria were as follows: (1) those with abnormal liver functions and renal insufficiency; (2) those who were in pregnancy or lactation period; (3) those with other rheumatoid immune diseases such as systemic lupus erythematosus, ankylosing spondylitis, and severe osteoarthritis; (4) those with the mental disorders or patients who could not coordinate with others due to the mental retardation; (5) those with the severe diseases in vital organs such as respiration, digestion, cerebrovascular; and (6) those who were also participating in other experiments.

2.3. Methods

2.3.1. Detection of MSUS. The color doppler ultrasound (manufacturer: Shenzhen Baisheng Medical Technology Co., Ltd.; model: CARIS) was used for examination. The patients were informed of the attention points before detection, and the detection was carried out when the patient’s spirit and emotions were in a stable state. The proximal digital joints, wrist joint, carpometacarpal joint, and knee joint were scanned by conventional imaging using the model of high-frequency ultrasound. The scanning direction was consistent with the long axis of the muscle, and the patients were advised to relax the muscle during the detection. If the abnormality was detected in the above joints, the abnormal position should be examined by cross-sectional scan to compare and analyze the cross-sectional scanning images and scanning images by conventional imaging to determine the effusion and swelling of the affected joint. The specific modes of ultrasonic scan in joints were as follows: (1) The probe should be placed in the anterior segment of the shoulder joint in a horizontal position when scanning the shoulder joint. After the position in the long head of biceps tendon and the intertubercular sulcus of the femur was determined by conventional scanning, the axis of the long head of the biceps tendon was taken as the scanning direction. It should be gradually scanned from the subscapular tendon to the position of the supraspinatus, inferior gemellus muscle, and teres minor. (2) When scanning the hip joint, the ultrasound probe was placed in the parallel position of the femoral neck after the patients were in a supine position to perform the anterior scan, and the joint imaging in the femoral head and femoral neck were gradually scanned. (3) The scanning in longitudinal position and transverse position was performed when scanning the proximal finger joint and carpometacarpal joint to observe the tendon around the joint, joint surface, and joint cavity effusion in turn and the changes in morphology. (4) When scanning the knee joint, the patients were in a supine position to make them buckle the knee joint in the lower limb of the affected side, and the ultrasonic probe was placed above the apex of the patella. The cutting position in declivity was...
2.3.2. Semiquantitative Score. (1) Synovial proliferation. The normal range was 0 points. The periosteal proliferation was confined to the joint angle and did not exceed the connection of the highest peak in bone surface, which was 1 point. The periosteal proliferation exceeded the connection of the highest peak in bone surface, but it did not extend to the backbone as 2 points. The periosteal proliferation extended to the backbone at 3 points. (2) Bone erosion. The normal range was 0 points. The cortical bone was surface roughness without defect as 1 point, the obvious bone defect was 2 points, and the bone defect with a larger area was 3 points. (3) Joint cavity effusion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (4) Intrasynovial blood signals. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (5) Synovial proliferation. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (6) Synovial proliferation. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (7) Joint cavity effusion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (8) Intrasynovial blood signals. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (9) Bone erosion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (10) Synovial proliferation. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (11) Bone erosion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (12) Joint cavity effusion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (13) Intrasynovial blood signals. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (14) Bone erosion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (15) Synovial proliferation. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (16) Joint cavity effusion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (17) Intrasynovial blood signals. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (18) Bone erosion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (19) Synovial proliferation. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (20) Joint cavity effusion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (21) Intrasynovial blood signals. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (22) Bone erosion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (23) Synovial proliferation. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (24) Joint cavity effusion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (25) Intrasynovial blood signals. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (26) Bone erosion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (27) Synovial proliferation. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (28) Joint cavity effusion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (29) Intrasynovial blood signals. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points. (30) Bone erosion. The normal range was 0 points, the paucity was 1 point, the medium was 2 points, and the mass was 3 points.

2.4. Evaluation of the Oswestry Disability Index. The rating scale of the ODI [15] was used to evaluate the effect of pain on the daily activities of RA patients. There were 10 items on the scale, including the evaluation of three fields, namely, pain (degree of pain and the effect of pain on sleep), monomodal function (lifting weight, sitting, standing, and walking), and individual comprehensive function (daily activity ability, sexual life, social activities, and outing). The lowest and the highest scores for each item were 0 and 5 points. The higher the score, the more serious the dysfunction of patients. 100 questionnaires were given out and recovered in this study, with an effective rate of 100%.

2.5. Observation Indices. The Spearman correlation analysis was used to study the relationship between the degree of illness of patients and parameters of MSUS and ODI.

2.6. Statistic Treatment. The experimental data were analyzed and processed by SPSS21.0, and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was used to draw pictures of the data. The study data including enumeration data and measurement data were tested by $\chi^2$ and $t$-test, indicated by (n (%)) and (± s). When $P < 0.05$, the differences were considered to be statistically significant.

### Table 1: Comparison of semiquantitative scores of MSUS in each group (± s).

| Groups         | n  | Synovial proliferation | Bone erosion | Joint cavity effusion | Intrasynovial blood signals | Total score |
|----------------|----|------------------------|--------------|-----------------------|-----------------------------|-------------|
| Remission group| 25 | 0.83 ± 0.07            | 0.78 ± 0.13  | 0.48 ± 0.09           | 0.59 ± 0.09                 | 2.68 ± 1.13 |
| Low activity group| 25 | 2.95 ± 0.15            | 1.20 ± 0.18  | 1.08 ± 0.13           | 1.37 ± 0.20                 | 6.63 ± 0.42 |
| Middle activity group| 25 | 4.11 ± 0.20            | 2.01 ± 0.23  | 2.01 ± 0.25           | 1.98 ± 0.33                 | 10.03 ± 0.56 |
| High activity group| 25 | 7.08 ± 0.70            | 2.15 ± 0.62  | 2.42 ± 0.18           | 2.61 ± 0.24                 | 14.26 ± 1.24 |

*indicates a significant difference in total score between the low activity group and the remission group ($t = 44.921, P < 0.001$). #indicates a significant difference in total score between the middle activity group and the remission group ($t = 63.925, P < 0.001$). *indicates a significant difference in total score between the high activity group and the remission group ($t = 46.439, P < 0.001$).

3. Results

3.1. Comparison of Semiquantitative Scores of MSUS in Each Group. The total semiquantitative score of MSUS in the remission group was obviously lower than that in the other three groups ($P < 0.001$). See details in Table 1.

3.2. Correlation between the Degree of Illness and Parameters of MSUS. The degree of illness in elderly patients with RA was positively correlated with parameters of MSUS ($r = 0.886, P < 0.001$). See details in Figure 1.

3.3. Rating Scale of the ODI in Each Group. The ODI score in the remission group was obviously lower than that in the other three groups ($P < 0.001$). See details in Table 2.

3.4. Correlation between the Degree of Illness and ODI. The degree of illness in elderly patients with RA was positively correlated with ODI ($r = 0.907, P < 0.001$). See details in Figure 2.

4. Discussion

The pathological changes of RA manifest as an inflammatory response of synovial joints first, and a large number of new blood vessels form with the invasiveness of inflammatory cells, thereby developing into pannus, whose presence can damage cartilage tissue and joint function. Previous studies have suggested that histopathological changes only occur when RA develops to the end stage, but subsequent studies have found that histopathological changes have occurred in the 6th–12th week of the inflammatory response of synovial membrane, and early intervention on diagnosis and treatment can effectively organize the disease progression, thus improving the prognosis. Therefore, early diagnosis and accurate assessment of the severity of RA have a great significance in improving prognosis [16], and early diagnosis and assessment of RA are mainly by imaging examination in the clinic. Characterized by no wound, simple operation, and repeated examination, MSUS can effectively avoid the radiation injuries of CT and X-ray examination. Compared with MRI, MSUS has a lower inspection cost, and its diagnostic value has been confirmed in the diseases like traumatic superficial soft tissue injury and chronic low back pain [17]. However, in terms of the diagnosis of RA, MSUS can make use of a high-frequency probe to observe the superficial joints better, analyze the direction and velocity of
blood flow by transforming into color images related to blood vessels using ultrasound, better identify the effusion and synovial proliferation in the joint cavity of patients with RA, and explore the rich blood flow signals of pannus during inflammatory activity, so as to better reflect the bone metabolic status and objectively evaluate the state of osteonecrosis in patients. Bone erosion and periosteal proliferation are the main lesions of RA, and the semiquantitative scoring system can be used to evaluate various lesions of RA in the clinic to determine the degree and location of lesions in patients [17]. Relevant literature has pointed out that MSUS can observe the tissues and organs in vivo in real time, which is suitable for displaying the morphology and interaction of muscles, tendons, bones, and joints in active, passive, or resistant motion states, and is conducive to the diagnosis of exercise-related diseases and impaction syndrome [18]. In this study, the scores were evaluated according to different grades, which were summarized as remission stage, low activity stage, middle activity stage, and high activity stage. With the increase in disease degree, the semiquantitative scores of MSUS in different groups would increase, indicating that the consistency between diagnosis of MSUS and disease degree was good. The degree of illness in elderly patients with RA was positively correlated with parameters of MSUS ($r = 0.886$, $P < 0.001$), which was consistent with the results of Zaragoza-García Oscar et al [19]. At the same time, Naqvi Atta Abbas et al. [20] showed that the DAS28 score was used to evaluate the condition of patients diagnosed with RA, and the analysis found that the semiquantitative score of MSUS increased significantly with the increase of the disease severity of RA, suggesting that the semiquantitative score of MSUS can determine the condition of RA. In addition, Sandoughi Mahnaz et al. [21] randomly selected 380 patients with RA as the research subjects. After analysis, it was found that the total score of assessment on MSUS was positively correlated with the swollen joint count and tender joint count in RA and was positively correlated with the degree of disease in patients with RA, considering that the MSUS score was closely related to the condition of RA. The above results confirmed that there was a close correlation between the parameters of MSUS and the severity of patients with RA, which is convenient to provide relevant reference data for the diagnosis and treatment of diseases.

RA is a common disease in clinics, and practical and simple assessment methods are particularly important in judging conditions, guiding treatment, observing the curative effect, and estimating prognosis [22]. The international general scales are used to evaluate the function of patients, so as to facilitate the comparison of clinical data and the development of multicountry and multicenter clinical research experiments [23]. ODI is the most commonly used scale to evaluate the dysfunction of low back pain in the world, which has been translated into Chinese by domestic scholars, with the reliability of the repeated test after Chinesization as high as 0.95, and the Chinese version is clear and easy to understand, which provides a further basis for clinical application in China [24]. The results of this study showed that the ODI score in the remission group was obviously lower than that in the other three groups, indicating that RA patients with more severe illness have a higher ODI. At the same time, the results of this study showed that the degree of illness in elderly patients with RA was positively correlated with ODI ($r = 0.907$, $P < 0.001$), which was consistent with the findings of Wang Jiawei et al.
[25]. The reason is that the ODI scale is fairly comprehensive, with good preciseness and professionalism in some aspects like structure, verbal expression, and content, and patients can fully understand the content of the scale in self-assessment, thus providing a good reference for the evaluation of the condition in clinic. The shortcomings of this study were as follows. First of all, the cases selected in this study were all patients in the local hospitals, with a single source of cases. Second, a sufficient sample size was not included in this study due to the limited observation time, resulting in the bias of study results. Finally, there is an inherent selection bias in a retrospective study, such as technology differences of staff in MSUS examination. Therefore, the study design should be improved, the sample size should be increased, and the relationship between the degree of illness in elderly patients with RA and parameters of MSUS and ODI, and the clinical value should be discussed in detail from multiple perspectives and aspects in the future. In summary, the preliminary conclusions obtained by this study still need to be further improved.

Data Availability

The data used to support the findings of this study are available upon reasonable request from the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] H. Nawaz, A. Ali, T. Rehman, and A. Aslam, “Chronological effects of non-steroidal anti-inflammatory drug therapy on oxidative stress and antioxidant status in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 40, no. 5, pp. 1767–1778, 2021.

[2] D. Szewczyk, T. Sadura-Sieklucka, B. Sokolowska, and K. Ksiezeopolska-Orlowska, "Improving the quality of life of patients with rheumatoid arthritis after rehabilitation irrespective of the level of disease activity," Rheumatology International, vol. 41, no. 4, pp. 781–786, 2021.

[3] H.-J. Chen, H.-R. Yang, Y. Zhi, Q. Q. Yao, and B. Liu, “Evaluation of pyrrolidine-based analog of jaspline B as potential SphK1 inhibitors against rheumatoid arthritis,” Bioorganic and Medicinal Chemistry Letters, vol. 34, Article ID 127754, 2021.

[4] T. Shimizu, Y. Nagafuchi, H. Harada et al., “Decreased peripheral blood memory B cells are associated with the presence of interstitial lung disease in rheumatoid arthritis: a case-control study,” Modern Rheumatology, vol. 31, no. 1, pp. 127–132, 2021.

[5] D. Alsharari, L. Obeidat, H. Khasawneh et al., “Rheumatoid arthritis interstitial lung disease: measuring and predictive factors among patients treated in rehabilitation clinics at royal medical services,” Medical Archives, vol. 74, no. 6, pp. 450–454, 2020.

[6] S. Mattias, S. Lars, S. Rantapää-Dahlgvist, and W. J. Solveig, “Trends in mortality, co-morbidity and treatment after acute myocardial infarction in patients with rheumatoid arthritis 1998-2013,” European Heart Journal Acute Cardiovascular Care, vol. 9, pp. 931–938, 2020.

[7] Q. Wang, J. P. Ruiz, and P. D. Hart, “Case report: a man with untreated rheumatoid arthritis, cryoglobulinemic vasculitis, membranous nephropathy and pulmonary sarcoïdosis,” BMC Nephrology, vol. 21, no. 1, p. 496, 2020.

[8] Y. Abe, K. Saeki, H. Dobashi et al., “Clinical characteristics and social productivity levels of patients with malignant rheumatoid arthritis based on a nationwide clinical database in Japan: annual survey from 2003 to 2013,” Modern Rheumatology, vol. 31, no. 3, pp. 621–628, 2021.

[9] K. M. Latcha, K. B. Leppenthin, M. Östergaard et al., “Cognitive behavioural therapy for insomnia in patients with rheumatoid arthritis: protocol for the randomised, single-blinded, parallel-group Sleep-RA trial,” Trials, vol. 21, no. 1, p. 440, 2020.

[10] S. Zhang, T. Meng, C. Tang et al., “MicroRNA-340-5p suppressed rheumatoid arthritis synovial fibroblast proliferation and induces apoptotic cell number by targeting signal transducers and activators of transcription 3,” Autoimmunity, vol. 53, no. 6, pp. 314–322, 2020.

[11] S. Jung-Hua, Y. Kuang-Hui, and C. Su-Hui, "Effectiveness of a self-management program for joint protection and physical activity in patients with rheumatoid arthritis: a randomized controlled trial,” International Journal of Nursing Studies, vol. 116, Article ID 103752, 2021.

[12] C. Ru-Xuan, Li-D. Zhao, and X. Xin-Yue, “Distinctive clinical characteristics and outcome of ILD-onset rheumatoid arthritis and ACPA-positive ILD: a longitudinal cohort of 282 cases,” Clinical Reviews in Allergy and Immunology, vol. 60, pp. 46–54, 2021.

[13] World Medical Association, “World medical association declaration of Helsinki: ethical principles for medical research involving human subjects,” JAMA, vol. 310, no. 20, pp. 2191–2194, 2013.

[14] K. Sadia, Z. Alam, and B. Saira, “Association of tumour necrosis factor-alpha -308 G/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis,” Journal of Ayub Medical College, Abbottabad, vol. 32, pp. 184–188, 2020.

[15] A. H. Hasanin and R. H. Mohamed, "Telmisartan alone or in combination with etanercept improves anemia associated with rheumatoid arthritis in rats: a possible role of anti-inflammatory and renal-protective effects," Pharmacological Reports, vol. 72, no. 2, pp. 379–388, 2020.

[16] T. Kelkka, P. Savola, D. Bhattacharya et al., “Adult-onset anti-citrullinated peptide antibody-negative destructive rheumatoid arthritis is characterized by a disease-specific CD8+ T lymphocyte signature,” Frontiers in Immunology, vol. 11, Article ID 578848, 2020.

[17] N. T. B. de Oliveira, N. A. Ricci, Y. R. dos Santos Franco, E. M. E. S. Salvador, L. C. B. Almeida, and C. M. N Cabral, "Effectiveness of the Piates method versus aerobic exercises in the treatment of older adults with chronic low back pain: a randomized controlled trial protocol,” BMC Musculoskeletal Disorders, vol. 20, no. 1, p. 250, 2019.

[18] L. Wagner, W. E. Haefeli, U. Merle et al., “A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19,” Cytokine, vol. 138, Article ID 155399, 2021.

[19] O. Zaragoza-García, I. P. Guzmán, M. E. Moreno-Godínez et al., "PON-1 haplotype (-108C-T, L55M, and Q192R) modulates the serum levels and activity PONase promoting an
atherogenic lipid profile in rheumatoid arthritis patients,” *Clinical Rheumatology*, vol. 40, no. 2, pp. 741–752, 2021.

[20] A. A. Naqvi, M. A. Hassali, W. Ifat et al., “Cross-culture adaptation and validation of English version of rheumatoid arthritis knowledge assessment scale (RAKAS) in patients with rheumatoid arthritis,” *International Journal of Rheumatic Diseases*, vol. 23, no. 7, pp. 918–927, 2020.

[21] S. Mahnaz, K. M. Ali, and L. Elnaz, “Effects of dehydroepiandrosterone on quality of life in premenopausal women with rheumatoid arthritis: a preliminary randomized clinical trial,” *International Journal of Rheumatic Diseases*, vol. 23, pp. 1692–1697, 2020.

[22] W. Weng, F. Wang, X. He, K. Zhou, and X. Wu, “Protective effect of corynoline on the CFA-induced rheumatoid arthritis via attenuation of oxidative and inflammatory mediators,” *Molecular and Cellular Biochemistry*, vol. 476, no. 2, pp. 831–839, 2021.

[23] A. D. Petro, J. Dougherty, B. R. England et al., “Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis,” *International Immunopharmacology*, vol. 91, Article ID 107260, 2021.

[24] P. Qing and Y. Liu, “Inhibitory role of long non-coding RNA OIP5-AS1 in rheumatoid arthritis progression through the microRNA-448-paraoxonase 1-toll-like receptor 3-nuclear factor κB axis,” *Experimental Physiology*, vol. 105, no. 10, pp. 1708–1719, 2020.

[25] J. Wang, Y. Li, L. Li, J. Yang, and J. Kopecek, “Exploration and evaluation of therapeutic efficacy of drug-free macromolecular therapeutics in collagen-induced rheumatoid arthritis mouse model,” *Macromolecular Bioscience*, vol. 20, no. 5, Article ID e1900445, 2020.